



## **Amicus Therapeutics Announces Presentation and Poster at the 23rd International Congress of the World Muscle Society**

October 2, 2018

CRANBURY, N.J., Oct. 02, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), today announced that an oral presentation and a poster highlighting its development program AT-GAA for Pompe disease will be included at the [23rd International Congress of the World Muscle Society](#), to be held October 2-6, 2018 in Mendoza, Argentina.

Oral Platform Presentation:

- Results From ATB200-02: First-in-Human Study of ATB200 Co-Administered With AT2221 for Pompe Disease (18 Month Results) (Friday, October 5 at 12:20pm ART (11:20am EDT)) - Dr. Benedikt Schoser, senior consultant at the Friedrich-Baur Institute, Dept. of Neurology at the Ludwig-Maximilians-University of Munich, Germany and Principal Investigator in the ATB200-02 study

Poster Session:

- A Novel Recombinant Human Acid Alpha-glucosidase, ATB200, Co-administered with a Pharmacological Chaperone, Leads to Greater Substrate Reduction and Improvement in Pompe Disease-relevant Markers Compared to Alglucosidase Alfa in Gaa KO Mice (Friday, October 5 at 5:00pm ART (4:00pm EDT)) – Yi Lun, Amicus Therapeutics

The World Muscle Society is a multidisciplinary Society, reflecting in particular the different disciplines involved in the study of neuromuscular disorders and the management of patients with these disorders. The aims of the WMS are: to provide a multidisciplinary scientific forum to advance and disseminate knowledge in the neuromuscular field for the benefit of patients; to stimulate, encourage and help to develop programs for professionals working in the neuromuscular field; to encourage multidisciplinary collaboration; to provide opportunities for young investigators in the neuromuscular field; and to promote the achievement of standards in clinical practice. The means for achieving these aims are: the organization of regular meetings to exchange scientific information; the organization of teaching courses; the promotion of international collaborative research and training; and the publication of reports.

### **About Amicus Therapeutics**

Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information please visit the company's website at [www.amicusrx.com](http://www.amicusrx.com).

### **Investors:**

Amicus Therapeutics  
Sara Pellegrino, IRC  
Vice President, Investor Relations & Corporate Communications  
[spellegrino@amicusrx.com](mailto:spellegrino@amicusrx.com)  
(609) 662-5044

### **Media / Multimedia Assets:**

Pure Communications  
Jennifer Paganelli  
[jpaganelli@purecommunications.com](mailto:jpaganelli@purecommunications.com)  
(347) 658-8290

FOLD-G



Source: Amicus Therapeutics, Inc.